TRAIL as a target in anti-cancer therapy

Cancer Letters

Volumn 285, Issue 1, 2009, Pages 1-5

  Wu, Gen Sheng ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Chemosensitivity; Drug development; TRAIL

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BEVACIZUMAB; CARBOPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PACLITAXEL; PROTEIN P53; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RETINOIC ACID; RETINOID; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CHONDROSARCOMA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; GENE EXPRESSION REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTOMA; MARGINAL ZONE LYMPHOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; SOLID TUMOR; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TREATMENT OUTCOME; UP-REGULATION;

EID: 70149122276     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.029     Document Type: Review

References (68)

1. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 2 (2002) 153-164
2. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
3. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
4. Jin Z., and El-Deiry W.S. Overview of cell death signaling pathways. Cancer Biol. Ther. 4 2 (2005) 139-163
5. Kischkel F.C., Hellbardt S., Behrmann I., et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14 (1995) 5579-5588
6. Ashkenazi A., and Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest. 118 6 (2008) 1979-1990
7. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 7 12 (2008) 1001-1012
8. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
9. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 (1996) 12687-12690
10. Mongkolsapaya J., Grimes J.M., Chen N., et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat. Struct. Biol. 6 11 (1999) 1048-1053
11. Pan G., O'Rourke K., Chinnaiyan A.M., et al. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
12. Wu G.S., Burns T.F., McDonald E.R., et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17 (1997) 141-143
13. MacFarlane M., Ahmad M., Srinivasula S.M., Fernandes-Alnemri T., Cohen G.M., and Alnemri E.S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 272 (1997) 25417-25420
14. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., and Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815-818
15. Walczak H., Degli-Esposti M.A., Johnson R.S., et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16 (1997) 5386-5397
16. Screaton G.R., Mongkolsapaya J., Xu X.N., Cowper A.E., McMichael A.J., and Bell J.I. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7 (1997) 693-696
17. Degli-Esposti M.A., Smolak P.J., Walczak H., et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186 (1997) 1165-1170
18. Sheridan J.P., Marsters S.A., Pitti R.M., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
19. Mongkolsapaya J., Cowper A.E., Xu X.N., et al. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. J. Immunol. 160 (1998) 3-6
20. Pan G., Ni J., Yu G., Wei Y.F., and Dixit V.M. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 424 (1998) 41-45
21. Marsters S.A., Sheridan J.P., Pitti R.M., et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7 (1997) 1003-1006
22. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., and Goodwin R.G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7 (1997) 813-820
23. Emery J.G., McDonnell P., Burke M.B., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273 (1998) 14363-14367
24. Wu G.S., Burns T.F., Zhan Y., Alnemri E.S., and El-Deiry W.S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59 (1999) 2770-2775
25. Almasan A., and Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14 3-4 (2003) 337-348
26. Pai S., Wu G.S., Ozoren N., Wu L., Jen J., Sidransky D., and El-Deiry W.S. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res. 58 16 (1998) 3513-3518
27. Hopkins-Donaldson S., Ziegler A., Kurtz S., et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 10 3 (2003) 356-364
28. Burns T.F., and El-Deiry W.S. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J. Biol. Chem. 276 41 (2001) 37879-37886
29. Kim Y., Suh N., Sporn M., and Reed J.C. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277 25 (2002) 22320-22329
30. Hietakangas V., Poukkula M., Heiskanen K.M., Karvinen J.T., Sistonen L., and Eriksson J.E. Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol. Cell Biol. 23 4 (2003) 1278-1291
31. Sun S.Y., Yue P., Zhou J.-Y., et al. Overexpression of bcl2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. BBRC 280 (2001) 788-797
32. Deng Y., Lin Y., and Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16 1 (2002) 33-45
33. Cummins J.M., Kohli M., Rago C., Kinzler K.W., Vogelstein B., and Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res. 64 9 (2004) 3006-3008
34. Chawla-Sarkar M., Bae S.I., Reu F.J., Jacobs B.S., Lindner D.J., and Borden E.C. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11 8 (2004) 915-923
35. Trauzold A., Wermann H., Arlt A., et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 20 31 (2001) 4258-4269
36. Ehrhardt H., Fulda S., Schmid I., Hiscott J., Debatin K.M., and Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22 25 (2003) 3842-3852
37. Baader E., Toloczko A., Fuchs U., et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res. 65 17 (2005) 7888-7895
38. Secchiero P., Gonelli A., Carnevale E., et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107 17 (2003) 2250-2256
39. Secchiero P., Zerbinati C., Rimondi E., et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol. Life. Sci. 61 15 (2004) 1965-1974
40. Trauzold A., Siegmund D., Schniewind B., et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25 56 (2006) 7434-7439
41. Ricci M.S., Kim S.H., Ogi K., et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer cell 12 1 (2007) 66-80
42. Wu G.S., Burns T.F., McDonald E.R., et al. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth. Oncogene 18 (1999) 6411-6418
43. Sheikh M.S., Burns T.F., Huang Y., et al. P53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 58 8 (1998) 1593-1598
44. Guan B., Yue P., Lotan R., and Sun S.Y. Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene 21 20 (2002) 3121-3129
45. Guan B., Yue P., Clayman G.L., and Sun S.Y. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J. Cell. Physiol. 188 1 (2001) 98-105
46. Gong B., and Almasan A. Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem. Bioph. Res. Commun. 278 3 (2000) 747-752
47. Wang Q., Ji Y., Wang X., and Evers B.M. Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem. Biophys. Res. Commun. 276 2 (2000) 466-471
48. Clarke N., Jimenez-Lara A.M., Voltz E., and Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. Embo J. 23 15 (2004) 3051-3060
49. Kirshner J.R., Karpova A.Y., Kops M., and Howley P.M. Identification of TRAIL as an interferon regulatory factor 3 transcriptional target. J. Virol. 79 14 (2005) 9320-9324
50. Rivera-Walsh I., Waterfield M., Xiao G., Fong A., and Sun S.C. NF-kappaB signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-I Tax-induced T-cell death. J. Biol. Chem. 276 44 (2001) 40385-40388
51. Baetu T.M., Kwon H., Sharma S., Grandvaux N., and Hiscott J. Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J. Immunol. 167 6 (2001) 3164-3173
52. Altucci L., Rossin A., Raffelsberger W., Reitmair A., Chomienne C., and Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 7 6 (2001) 680-686
53. Nebbioso A., Clarke N., Voltz E., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11 (2005) 77-84
54. Insinga A., Monestiroli S., Ronzoni S., et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11 (2005) 71-76
55. Xu J., Zhou J.Y., and Wu G.S. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor {alpha}-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res. 66 20 (2006) 10092-10099
56. Xu J., Zhou J.Y., Tainsky M.A., and Wu G.S. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-aza-2′-deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res. 67 3 (2007) 1203-1211
57. Xu J., Zhou J.Y., Wei W.Z., Philipsen S., and Wu G.S. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res. 68 16 (2008) 6718-6726
58. Kuribayashi K., Krigsfeld G., Wang W., et al. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol. Ther. 7 12 (2008)
59. Walczak H., Miller R.E., Ariail K., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 2 (1999) 157-163
60. Ashkenazi A., Holland P., and Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 26 21 (2008) 3621-3630
61. Jo M., Kim T.H., Seol D.W., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6 5 (2000) 564-567
62. Lawrence D., Shahrokh Z., Marsters S., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7 4 (2001) 383-385
63. Hao C., Song J.H., Hsi B., et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 64 23 (2004) 8502-8506
64. Herbst R., Mendolson D., Ebbinghaus S., et al. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. P. Am. Soc. Clin. Oncol. 24 (2006) 3013
65. Nagane M., Pan G., Weddle J.J., Dixit V.M., Cavenee W.K., and Huang H.J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60 4 (2000) 847-853
66. Cuello M., Ettenberg S.A., Nau M.M., and Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol. 81 3 (2001) 380-390
67. Yee L., Fanale K., Dimick S., et al. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. J. Clin. Oncol. 25 No 18S (June 20 Suppl.) (2007) 8078
68. Soria J., Smit E.F., Khayat D., et al. Phase Ib study of recombinant human (rh) Apo2L/TRAIL in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 26 No 15S (May 20 Suppl.) (2008) 3539